235 related articles for article (PubMed ID: 27401508)
1. Impact of Prophylactic Fentanyl Pectin Nasal Spray on Exercise-Induced Episodic Dyspnea in Cancer Patients: A Double-Blind, Randomized Controlled Trial.
Hui D; Kilgore K; Park M; Williams J; Liu D; Bruera E
J Pain Symptom Manage; 2016 Oct; 52(4):459-468.e1. PubMed ID: 27401508
[TBL] [Abstract][Full Text] [Related]
2. Effect of Prophylactic Fentanyl Buccal Tablet on Episodic Exertional Dyspnea: A Pilot Double-Blind Randomized Controlled Trial.
Hui D; Kilgore K; Frisbee-Hume S; Park M; Liu D; Balachandran DD; Bruera E
J Pain Symptom Manage; 2017 Dec; 54(6):798-805. PubMed ID: 28803087
[TBL] [Abstract][Full Text] [Related]
3. Effects of prophylactic subcutaneous fentanyl on exercise-induced breakthrough dyspnea in cancer patients: a preliminary double-blind, randomized, controlled trial.
Hui D; Xu A; Frisbee-Hume S; Chisholm G; Morgado M; Reddy S; Bruera E
J Pain Symptom Manage; 2014 Feb; 47(2):209-17. PubMed ID: 23830530
[TBL] [Abstract][Full Text] [Related]
4. Prophylactic Fentanyl Sublingual Spray for Episodic Exertional Dyspnea in Cancer Patients: A Pilot Double-Blind Randomized Controlled Trial.
Hui D; Hernandez F; Larsson L; Liu D; Kilgore K; Naberhuis J; Virgilio A; Reddy S; Reddy A; Dalal S; Haider A; Driver L; Azhar A; Dev R; Bruera E
J Pain Symptom Manage; 2019 Oct; 58(4):605-613. PubMed ID: 31276809
[TBL] [Abstract][Full Text] [Related]
5. A report on the long-term use of fentanyl pectin nasal spray in patients with recurrent breakthrough pain.
Taylor D; Radbruch L; Revnic J; Torres LM; Ellershaw JE; Perelman M
J Pain Symptom Manage; 2014 Jun; 47(6):1001-7. PubMed ID: 24128821
[TBL] [Abstract][Full Text] [Related]
6. Intranasal fentanyl versus fentanyl pectin nasal spray for the management of breakthrough cancer pain in doses proportional to basal opioid regimen.
Mercadante S; Prestia G; Adile C; Casuccio A
J Pain; 2014 Jun; 15(6):602-7. PubMed ID: 24561001
[TBL] [Abstract][Full Text] [Related]
7. A multicenter, placebo-controlled, double-blind, multiple-crossover study of Fentanyl Pectin Nasal Spray (FPNS) in the treatment of breakthrough cancer pain.
Portenoy RK; Burton AW; Gabrail N; Taylor D;
Pain; 2010 Dec; 151(3):617-624. PubMed ID: 20800358
[TBL] [Abstract][Full Text] [Related]
8. Facilitation of accurate and effective radiation therapy using fentanyl pectin nasal spray (FPNS) to reduce incidental breakthrough pain due to procedure positioning.
Prieto I; Pardo J; Luna J; Marin JP; Olivera J; Garcia AJ; Perez AM
Scand J Pain; 2016 Apr; 11():52-58. PubMed ID: 28850470
[TBL] [Abstract][Full Text] [Related]
9. Long-term safety, tolerability, and consistency of effect of fentanyl pectin nasal spray for breakthrough cancer pain in opioid-tolerant patients.
Portenoy RK; Raffaeli W; Torres LM; Sitte T; Deka AC; Herrera IG; Wallace MS;
J Opioid Manag; 2010; 6(5):319-28. PubMed ID: 21046929
[TBL] [Abstract][Full Text] [Related]
10. Fentanyl pectin nasal spray in breakthrough cancer pain.
Taylor D; Galan V; Weinstein SM; Reyes E; Pupo-Araya AR; Rauck R;
J Support Oncol; 2010; 8(4):184-90. PubMed ID: 20822038
[TBL] [Abstract][Full Text] [Related]
11. EffenDys-Fentanyl Buccal Tablet for the Relief of Episodic Breathlessness in Patients With Advanced Cancer: A Multicenter, Open-Label, Randomized, Morphine-Controlled, Crossover, Phase II Trial.
Simon ST; Kloke M; Alt-Epping B; Gärtner J; Hellmich M; Hein R; Piel M; Cornely OA; Nauck F; Voltz R
J Pain Symptom Manage; 2016 Nov; 52(5):617-625. PubMed ID: 27693898
[TBL] [Abstract][Full Text] [Related]
12. Fentanyl Pectin Nasal Spray Versus Oral Morphine in Doses Proportional to the Basal Opioid Regimen for the Management of Breakthrough Cancer Pain: A Comparative Study.
Mercadante S; Aielli F; Adile C; Costanzi A; Casuccio A
J Pain Symptom Manage; 2016 Jul; 52(1):27-34. PubMed ID: 27208863
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of fentanyl pectin nasal spray compared with immediate-release morphine sulfate tablets in the treatment of breakthrough cancer pain: a multicenter, randomized, controlled, double-blind, double-dummy multiple-crossover study.
Fallon M; Reale C; Davies A; Lux AE; Kumar K; Stachowiak A; Galvez R;
J Support Oncol; 2011; 9(6):224-31. PubMed ID: 22055892
[TBL] [Abstract][Full Text] [Related]
14. Long-term tolerability, efficacy and acceptability of fentanyl pectin nasal spray for breakthrough cancer pain.
Radbruch L; Torres LM; Ellershaw JE; Gatti A; Luis Lerzo G; Revnic J; Taylor D
Support Care Cancer; 2012 Mar; 20(3):565-73. PubMed ID: 21424794
[TBL] [Abstract][Full Text] [Related]
15. Fentanyl pectin nasal spray: in breakthrough pain in opioid-tolerant adults with cancer.
Lyseng-Williamson KA
CNS Drugs; 2011 Jun; 25(6):511-22. PubMed ID: 21649451
[TBL] [Abstract][Full Text] [Related]
16. Relationship between onset of pain relief and patient satisfaction with fentanyl pectin nasal spray for breakthrough pain in cancer.
Torres LM; Revnic J; Knight AD; Perelman M
J Palliat Med; 2014 Oct; 17(10):1150-7. PubMed ID: 25211772
[TBL] [Abstract][Full Text] [Related]
17. Opioids in patients with COPD and refractory dyspnea: literature review and design of a multicenter double blind study of low dosed morphine and fentanyl (MoreFoRCOPD).
van Dijk M; Mooren KJM; van den Berg JK; van Beurden-Moeskops WJC; Heller-Baan R; de Hosson SM; Lam-Wong WY; Peters L; Pool K; Kerstjens HAM
BMC Pulm Med; 2021 Sep; 21(1):289. PubMed ID: 34507574
[TBL] [Abstract][Full Text] [Related]
18. A pharmacokinetic assessment of an alternate titration strategy for fentanyl pectin nasal spray.
Perelman M; Knight A
Int J Clin Pharmacol Ther; 2013 Dec; 51(12):942-7. PubMed ID: 24120713
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of fentanyl sublingual spray for the treatment of breakthrough cancer pain: a randomized, double-blind, placebo-controlled study.
Rauck R; Reynolds L; Geach J; Bull J; Stearns L; Scherlis M; Parikh N; Dillaha L
Curr Med Res Opin; 2012 May; 28(5):859-70. PubMed ID: 22480131
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period.
Kress HG; Orońska A; Kaczmarek Z; Kaasa S; Colberg T; Nolte T
Clin Ther; 2009 Jun; 31(6):1177-91. PubMed ID: 19695386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
